Glioma News and Research

RSS

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).

Wake Forest University to begin clinical trial for low-grade gliomas

For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. Eighteen patients will be the first in the world to receive it.

2 Dec 2010

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.

22 Nov 2010

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier - a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.

18 Nov 2010

Frequent long-term use of cell phones may increase cancer risk

Public health concerns have been raised today about the safety of being exposed to radiofrequency (RF) radiation emitted from cell phones. A report released by the Ontario Agency for Health Protection and Promotion (OAHPP) in September 2010 was one of the studies cited as providing evidence that frequent long-term use of cell phones may be associated with an increased risk of cancer.

4 Nov 2010

Combination of DC-CIK and stem cell therapy effective to prevent cancer recurrence after surgery

"For brain cancer patients after surgery, the combined DC-CIK and stem cell therapy from Cellonis Biotechnologies can be a very effective method in preventing cancer recurrence," says renowned cancer doctor Dr. Dinggang Li.

4 Nov 2010

Long-term cell phone usage doubles risk of developing brain tumors

The highest-quality research data available suggests that long-term exposure to microwaves from cellular phones may lead to an increased risk of brain tumors, reports a paper in the November/December issue of Journal of Computer Assisted Tomography. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

2 Nov 2010

Antigenics third quarter net loss decreases from $10.8 million to $5.9 million

Antigenics Inc. reported today its results for the quarter ended September 30, 2010. The company incurred a net loss attributable to common stockholders of $5.9 million, or $0.06 per share, basic and diluted, for the third quarter of 2010, compared with a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, in the third quarter of 2009.

28 Oct 2010

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Antigenics, Inc. today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage® vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.

25 Oct 2010

New clinical trial to treat brain cancer launched

Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm together with immatics biotechnologies have launched the first clinical trial of a promising cancer vaccine to treat glioblastoma, one of the most common forms of brain cancer.

19 Oct 2010

Role of TGF-ß in cancer diseases

During this year's BIOTECHNICA exhibition, the international biotech news magazine „GEN - Genetic Engineering & Biotechnology News yesterday on 5 October 2010, held an information event with subsequent panel discussion featuring the topic TGF-ß an important target in cancer diseases.

7 Oct 2010

Gene alteration impacts brain tumor development: Study

The interaction between a network of altered genes appears to play an important role in the development and progression of brain tumors, according to a study in the July 15 issue of JAMA.

27 Sep 2010

immatics raises EUR53.8million in Series C financing round

immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that it has raised EUR53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics' existing pipeline of advanced therapeutic cancer vaccine candidates.

21 Sep 2010

Researchers identify novel approach to decrease glioblastoma multiforme recurrence

Researchers from the University of Massachusetts Medical School have identified a novel approach of combining chemotherapy with a targeted therapy to decrease the recurrence of glioblastoma multiforme, the most common and aggressive brain tumor.

25 Aug 2010

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prostate, the most aggressive form of malignant glioma, called a glioblastoma multiforme or GBM, has steadfastly defied advances in neurosurgery, radiation therapy and various conventional or novel drugs. But an international team of scientists, headed by researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine, reports in the August 15 issue of Genes & Development that they have discovered a new signaling pathway between GBM cells - one that, if ultimately blocked or disrupted, could significantly slow or reduce tumor growth and malignancy.

16 Aug 2010

Venom-based nanoparticles improve gene therapy for fighting glioma

An ingredient in the venom of the "deathstalker" scorpion could help gene therapy become an effective treatment for brain cancer, scientists are reporting. The substance allows therapeutic genes - genes that treat disease - to reach more brain cancer cells than current approaches, according to the study in ACS Nano, a monthly journal.

12 Aug 2010

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.

3 Aug 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

Research on method to open blood-brain barrier for safe cancer drug delivery

One of the human body's most powerful defensive tools, the blood-brain barrier is a chemical labyrinth that prevents toxins and viruses in the bloodstream from reaching the brain. This foolproof security system, however, limits the ability of physicians to deliver drugs directly to the brain, making it difficult to treat brain tumors. Researchers at Rensselaer Polytechnic Institute are endeavoring to solve this problem by investigating new methods for bypassing the blood-brain barrier and combating the spread of brain cancer.

28 Jul 2010

PecFent receives Positive Opinion from CHMP for treatment of BTCP

Archimedes Pharma, a leading specialty pharma company, today announced that its lead product, PecFent, has received a Positive Opinion from the Committee for Human Medicinal Products, of the European Medicines Agency. The CHMP is recommending PecFent, an innovative fentanyl nasal spray, be authorised for marketing in European Union countries for the treatment of breakthrough cancer pain - sudden, unpredictable episodes of intense pain that occur despite background pain medication.

25 Jun 2010

Conscious sedation for glioma resection shortens hospital stay

The recovery time and cost of brain-tumor surgery might both be reduced if surgery is performed while patients are awake during part of the procedure, according to a new study conducted at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

19 Jun 2010